Who are Ilumya Injectable Product's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mirikizumab - IV, Mirikizumab (MIR), Mirikizumab - SC, Mirikizumab - Intravenous (IV), Risankizumab (RISA), risankizumab SC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ilumya-injectable-product.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ilumya Injectable Product — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ilumya Injectable Product (Ilumya Injectable Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-23 inhibitor (monoclonal antibody). Area: Immunology/Dermatology.

marketed IL-23 inhibitor (monoclonal antibody) IL-23 p19 subunit Immunology/Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Ilumya Injectable Product (Ilumya Injectable Product) — Psoriasis Treatment Center of Central New Jersey. Ilumya (tildrakizumab) is a monoclonal antibody that selectively blocks the IL-23 pathway by binding to the p19 subunit of interleukin-23, reducing inflammatory signaling in psoriasis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ilumya Injectable Product TARGET	Ilumya Injectable Product	Psoriasis Treatment Center of Central New Jersey	marketed	IL-23 inhibitor (monoclonal antibody)	IL-23 p19 subunit
Mirikizumab - IV	Mirikizumab - IV	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Mirikizumab (MIR)	Mirikizumab (MIR)	Alimentiv Inc.	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Mirikizumab - SC	Mirikizumab - SC	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Mirikizumab - Intravenous (IV)	Mirikizumab - Intravenous (IV)	University of North Carolina, Chapel Hill	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
Risankizumab (RISA)	Risankizumab (RISA)	Caja Costarricense de Seguro Social	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit
risankizumab SC	risankizumab SC	AbbVie	phase 3	IL-23 inhibitor (monoclonal antibody)	IL-23 p19 subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-23 inhibitor (monoclonal antibody) class)

Janssen Research & Development, LLC · 2 drugs in this class
AbbVie · 1 drug in this class
Brigham and Women's Hospital · 1 drug in this class
Psoriasis Treatment Center of Central New Jersey · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ilumya Injectable Product — Competitive Intelligence Brief. https://druglandscape.com/ci/ilumya-injectable-product. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab